secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aurinia Pharmaceuticals Inc. (AUPH)
CIK:        0001600620
Form:       8-K
Filed at:   2024-09-12T23:59:59+00:00
Accession:  0001600620-24-000099
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aurinia restructures board: 3 directors resign, Kevin Tang appointed, CEO Greenleaf stays
--------------------------------------------------------------------------------

- Board accepted conditional resignations of Daniel Billen, Hector MacKay-Dunn, and Brinda Balakrishnan, effective Sept 9, 2024.
- CEO Peter Greenleaf remains director; Board cited exceptional circumstances for rejecting his conditional resignation.
- Kevin Tang, President of Tang Capital Management, appointed as director effective Sept 12, 2024.
- Board reduced from 9 to 7 members; Amended and Restated Bylaws now authorize Board to set director count.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600620/000160062024000099/0001600620-24-000099-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600620/000160062024000099/auph-20240909.htm
  HTML page:      https://secwatch.observer/filing/0001600620-24-000099

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer